Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

Cigarette smoke alters the invariant natural killer T cell function and may inhibit anti-tumor responses.

Hogan AE, Corrigan MA, O'Reilly V, Gaoatswe G, O'Connell J, Doherty DG, Lynch L, O'Shea D.

Clin Immunol. 2011 Sep;140(3):229-35. doi: 10.1016/j.clim.2011.01.011. Epub 2011 Feb 2.

PMID:
21684213
2.

Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.

Wu L, Gabriel CL, Parekh VV, Van Kaer L.

Tissue Antigens. 2009 Jun;73(6):535-45. doi: 10.1111/j.1399-0039.2009.01256.x. Epub 2009 Apr 8. Review.

PMID:
19392798
3.

iNKT cells in microbial immunity: recognition of microbial glycolipids.

Kinjo Y, Ueno K.

Microbiol Immunol. 2011 Jul;55(7):472-82. doi: 10.1111/j.1348-0421.2011.00338.x. Review.

4.

Natural killer T cells within the liver: conductors of the hepatic immune orchestra.

Swain MG.

Dig Dis. 2010;28(1):7-13. doi: 10.1159/000282059. Epub 2010 May 7. Review.

PMID:
20460885
5.

Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects.

Exley MA, Lynch L, Varghese B, Nowak M, Alatrakchi N, Balk SP.

Clin Immunol. 2011 Aug;140(2):184-95. doi: 10.1016/j.clim.2011.04.017. Epub 2011 May 13. Review.

6.

Invariant natural killer T cells and immunotherapy of cancer.

Molling JW, Moreno M, van der Vliet HJ, van den Eertwegh AJ, Scheper RJ, von Blomberg BM, Bontkes HJ.

Clin Immunol. 2008 Nov;129(2):182-94. doi: 10.1016/j.clim.2008.07.025. Epub 2008 Sep 9. Review.

PMID:
18783990
7.

The in vivo response of invariant natural killer T cells to glycolipid antigens.

Parekh VV, Lalani S, Van Kaer L.

Int Rev Immunol. 2007 Jan-Apr;26(1-2):31-48. Review.

PMID:
17454263
8.

The invariant NKT cell subset in anti-viral defenses: a dark horse in anti-influenza immunity?

Kulkarni RR, Haeryfar SM, Sharif S.

J Leukoc Biol. 2010 Oct;88(4):635-43. doi: 10.1189/jlb.0410191. Epub 2010 Jun 2. Review.

9.

Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer.

Motohashi S, Okamoto Y, Yoshino I, Nakayama T.

Clin Immunol. 2011 Aug;140(2):167-76. doi: 10.1016/j.clim.2011.01.009. Epub 2011 Jan 27. Review.

PMID:
21349771
10.

The specialized iNKT cell system recognizes glycolipid antigens and bridges the innate and acquired immune systems with potential applications for cancer therapy.

Taniguchi M, Tashiro T, Dashtsoodol N, Hongo N, Watarai H.

Int Immunol. 2010 Jan;22(1):1-6. doi: 10.1093/intimm/dxp104. Epub 2009 Oct 25. Review.

11.

Application of natural killer T cells in antitumor immunotherapy.

Hong C, Park SH.

Crit Rev Immunol. 2007;27(6):511-25. Review.

PMID:
18197797
12.

Flow cytometry for natural killer T cells: multi-parameter methods for multifunctional cells.

Metelitsa LS.

Clin Immunol. 2004 Mar;110(3):267-76. Review.

PMID:
15047204
13.

Invariant natural killer T cell-based immunotherapy for cancer.

Motohashi S, Nakayama T.

Immunotherapy. 2009 Jan;1(1):73-82. doi: 10.2217/1750743X.1.1.73. Review.

PMID:
20635975
14.

Harnessing invariant NKT cells in vaccination strategies.

Cerundolo V, Silk JD, Masri SH, Salio M.

Nat Rev Immunol. 2009 Jan;9(1):28-38. doi: 10.1038/nri2451. Review.

PMID:
19079136
15.

Switching invariant natural killer T (iNKT) cell response from anticancerous to anti-inflammatory effect: molecular bases.

Laurent X, Bertin B, Renault N, Farce A, Speca S, Milhomme O, Millet R, Desreumaux P, Hénon E, Chavatte P.

J Med Chem. 2014 Jul 10;57(13):5489-508. doi: 10.1021/jm4010863. Epub 2014 Feb 12. Review.

PMID:
24428717
16.

Induced pluripotency as a potential path towards iNKT cell-mediated cancer immunotherapy.

Watarai H, Yamada D, Fujii S, Taniguchi M, Koseki H.

Int J Hematol. 2012 Jun;95(6):624-31. doi: 10.1007/s12185-012-1091-0. Epub 2012 May 17. Review.

PMID:
22592322
17.

Interaction between invariant NKT cells and myeloid-derived suppressor cells in cancer patients: evidence and therapeutic opportunities.

Mussai F, De Santo C, Cerundolo V.

J Immunother. 2012 Jul;35(6):449-59. doi: 10.1097/CJI.0b013e31825be926. Review.

PMID:
22735803
18.

Structure-activity relationship studies of novel glycosphingolipids that stimulate natural killer T-cells.

Tashiro T.

Biosci Biotechnol Biochem. 2012;76(6):1055-67. Epub 2012 Jun 7. Review.

19.

Optimizing NKT cell ligands as vaccine adjuvants.

Carreño LJ, Kharkwal SS, Porcelli SA.

Immunotherapy. 2014;6(3):309-20. doi: 10.2217/imt.13.175. Review.

20.

Invariant natural killer T cells: bridging innate and adaptive immunity.

Van Kaer L, Parekh VV, Wu L.

Cell Tissue Res. 2011 Jan;343(1):43-55. doi: 10.1007/s00441-010-1023-3. Epub 2010 Aug 24. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk